Company: ACBM
Filing Date: 2025-07-18
Form Type: 10-K
Source: 0001640334-25-001245
Chunk: 434

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-18
Form: 10-K
Item: Item 6
Chunk 434
---
  Loss from operations  (8,804,367)  (15,869,737)         Other expense        Interest expense - related parties  3,206   1,706    Total other expenses  3,206   1,706          Loss before income tax expense  (8,807,573)  (15,871,443)Income tax expense   -   - Net loss $(8,807,573) $(15,871,443)         Basic and diluted loss per share of common stock $(0.15) $(0.26)         Weighted average number of shares of common stock outstanding  60,042,000   60,042,000 

The accompanying notes are an integral part of these financial statements.

 F-5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

  Preferred Stock  Common Stock  Additional Paid in   Deferred stock  Accumulated  Total Stockholders' Equity     Shares    Amount    Shares    Amount    Capital   compensation   Deficit  (Deficit)                          Balance, December 31, 2021  -  $-   60,042,000  $60,042  $32,293,530  $(23,773,383) $(7,936,482) $643,707                                  Amortization of deferred stock compensation   -   -   -   -   -   15,712,400   -   15,712,400 Imputed interest on related party loans  -   -   -   -   1,706   -   -   1,706 Net loss  -   -   -   -   -   -   (15,871,443)  (15,871,443)                                 Balance, December 31, 2022  -   -   60,042,000   60,042   32,295,236   (8,060,983)  (23,807,925)  486